AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
7 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Syndax Pharmaceuticals, Waltham, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Acute leukemias with KMT2A gene rearrangements (KMT2Ar) occur in both B and T acute lymphoblastic leukemia (B-ALL, T-ALL) and acute myeloid leukemia (AML). They arise from chromosomal translocations between KMT2A and genes involved in transcriptional elongation, such as MLLT3. DOT1L inhibitors and Menin inhibitors target the chromatin-associated protein complexes that sustain the leukemic gene expression program driven by KMT2A fusion proteins. The Menin inhibitor Revumenib (Rev) is now approved for patients with relapsed or refractory KMT2Ar acute leukemias. However, the small numbers of ALL patients enrolled on early clinical trials precludes knowing whether response rates are similar in ALL and AML.
To address this question, we sought to develop a model to systematically compare myeloid and lymphoid disease arising from the same KMT2A rearrangement. Using patient-derived breakpoints, we employed CRISPR/Cas9 homology directed repair to perform high-efficiency knock-in of truncated MLLT3 cDNA at the end of a relevant KMT2A exon along with the fluorescent reporter mNeonGreen in primary cord-blood derived human CD34+ hematopoietic stem and progenitor cells (HSPCs). Strikingly, KMT2A::MLLT3 expressing HSPCs transplanted in immunodeficient mice generate leukemias with blasts expressing either myeloid or lymphoid associated antigens. Both cell types can be isolated and grown in culture as either myeloid (MB) or lymphoid blasts (LB) thus providing a model of KMT2Ar AML and ALL generated from the same source and identical fusion protein.
To evaluate lineage specific drug responses, we titrated Rev or the DOT1L inhibitor compound 10 (C10) in matched cord-blood derived primary MBs and LBs leukemia lines. Surprisingly, LBs are markedly less sensitive to both single agent Rev and C10 compared to MBs and fail to downregulate key gene targets such as HOXA9 and MEIS1 demonstrating a lineage-specific response to these chromatin-targeted drugs. Chromatin localization studies reveal that, following Menin inhibition, KMT2A::MLLT3 remains bound at leukemia-associated loci, like HOXA cluster and MEIS1 in LBs despite loss of Menin occupancy. This is in direct contrast to MBs, where both Menin and KMT2A:MLLT3 are displaced. Critically, degradation of KMT2A::MLLT3 in both MBs and LBs using the dTAG/FKBP12F36V system results in equal downregulation of the leukemic gene expression program, further supporting a lineage-specific difference in response to the drugs. Notably, combined Menin and DOT1L inhibition is required to evict the fusion from chromatin in LBs, implicating H3K79me2 as an important factor in retained KMT2A::MLLT3 occupancy. This suggests that cellular lineage can influence response to targeted therapy even in the presence of the same oncogenic driver. To begin to understand why different lineages show differential responses, we performed KMT2A::MLLT3 immunofluorescence along with the nucleolar marker Fibrillarin in matched MBs and LBs. Rev alone and combined Rev and C10 treatment resulted in relocalization of the KMT2A::MLLT3 fusion protein from presumed nuclear condensates to the nucleolus in MBs, while only the combination treatment induced relocalization of KMT2A::MLLT3 in LBs. These data suggest a fundamental difference in KMT2A::MLLT3 condensate response and composition.
To verify drug-specific responses in patient-derived xenograft (PDX) models, we transplanted KMT2Ar AML and B-ALL PDX cells in immunodeficient mice. Strikingly, B-ALL PDXs failed to clear bone marrow disease at 28 days and succumbed to disease progression faster than previously reported for AML PDXs. RNA-seq from B-ALL PDXs revealed dampened gene expression response to Rev with no change in the key KMT2A:MLLT3 targets HOXA9 and MEIS1, while the AML PDXs showed strong downregulation. Unlike AML PDX’s where Menin and KMT2A:MLLT3 is evicted from chromatin, KMT2A ChIP-seq in B-ALL shows fusion protein retention at these loci in the absence of Menin. This explains the lack of gene expression changes in B-ALL. Finally, combination of Rev and C10 eradicates B-ALL by dramatically reducing disease burden with clearance of bone marrow disease at 28 days and long-term survival of mice up to 200 days without overt hematopoietic toxicity.
In conclusion, this study establishes novel models of human KMT2Ar acute leukemias and links drug response to lineage, suggesting fundamental differences in the fusion protein complex composition between myeloid and lymphoid disease.